Clinical efficacy of ONC201 in thalamic H3 K27M-mutant glioma.
Volume: 38, Issue: 15_suppl, Pages: 3617 - 3617
Published: May 20, 2020
Abstract
3617 Background: Diffuse midline gliomas, H3 K27M-mutant are associated with a poor prognosis compared to H3 wild-type gliomas and have no effective therapy following first-line radiation. ONC201 is a bitopic DRD2 antagonist and allosteric ClpP agonist that has shown encouraging single agent efficacy in recurrent H3 K27M-mutant gliomas located in various midline structures of the brain. In addition to tumor and immune cells, the pharmacodynamics...
Paper Details
Title
Clinical efficacy of ONC201 in thalamic H3 K27M-mutant glioma.
Published Date
May 20, 2020
Journal
Volume
38
Issue
15_suppl
Pages
3617 - 3617
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History